- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 .
View more information in the IUPHAR Pharmacology Education Project: infliximab
|Because infliximab was prepared from a murine hybridoma it suffers from the problem of allogenic antigenicity in humans, resulting in fhe generation of anti-infliximab antibodies which neutralizes its therapeutic efficacy. This problem has largely been overcome by the development of engineered antibodies such as 'chimeric', 'humanized' and 'fully human' antibody constructs which are minimally immunogenic.|
|Used in combination with methotrexate to reduce production of anti-infliximab antibodies. However, if infliximab is rendered ineffective, other anti-TNFα agents can be used as an alternative therapy.|
|Approved monoclonal antibody therapy for Crohn's disease.|
|Approved monoclonal antibody therapy for UC.|
|Immunopaedia Case Studies Links|
|Case of eye injury and decreased vision|